Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD207 CAR-T cells (Beijing Friendship Hospital)
- Development stage
- Unknown
- Lead developer
- Beijing Friendship Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CD207 CAR-T cells is an investigational chimeric antigen receptor (CAR) T-cell therapy being developed by Beijing Friendship Hospital for the treatment of relapsed and refractory Langerhans cell histiocytosis (LCH). The therapy consists of autologous T cells that have been genetically engineered to express a CAR targeting CD207 (also known as langerin). CD207 is a C-type lectin receptor and a defining marker for Langerhans cells, which are the cells that accumulate abnormally in LCH. By targeting this specific surface protein, the CAR-T cells are designed to selectively recognize and eliminate the pathological CD207-positive cells. The treatment is currently being evaluated in a Phase 1 clinical trial to assess its safety and efficacy in patients who have not responded to standard therapies.
- Other names
- CD207-targeted CAR-T cell therapyCD-207-targeted CAR-T cell therapyCD 207-targeted CAR-T cell therapyLangerin CAR-T cellsCD207 CAR-TCD-207 CAR-TCD 207 CAR-T
02
Targets
CD207 (Langerin)
Beyond the preview
Go deeper on CD207 CAR-T cells (Beijing Friendship Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD207 CAR-T cells (Beijing Friendship Hospital).